|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 7,431,943
This patent, issued on October 7, 2008, primarily covers a pharmaceutical composition involving a complex of a drug and a cyclodextrin. The patent aims to enhance drug solubility, bioavailability, and stability through specific inclusion complex formulations.
Patent Overview
- Title: "Drug cyclodextrin complexes and processes for their preparation"
- Applicants: Roche (United States)
- Priority Date: May 4, 2004
- Expiration: Likely 20 years from filing, i.e., around 2024, unless extension or terminal disclaimers applied.
- Field: Pharmaceutical formulations, particularly drug-cyclodextrin inclusion complexes.
Claims Breakdown
Independent Claims
The patent generally contains two independent claims (Claims 1 and 22), which define the core invention:
Claim 1:
A pharmaceutical composition comprising a complex of a drug and anhydrous cyclodextrin, where the drug is selected from a group such as itraconazole, and the complex is prepared by a process involving co-precipitation, spray drying, or lyophilization. The key feature is the inclusion of the drug within the cyclodextrin cavity, forming an inclusion complex with improved solubility.
Claim 22:
A process for preparing a drug-cyclodextrin complex, which includes mixing the drug with cyclodextrin and employing a specific process (e.g., spray drying), resulting in an inclusion complex with enhanced dissolution properties.
Dependent Claims
Dependent claims specify features such as:
- Use of particular cyclodextrin derivatives (e.g., methylated or hydroxypropyl-β-cyclodextrin).
- Specific molar ratios of drug to cyclodextrin.
- Characteristics of the complex (e.g., amorphous form, particulate size).
- Forms of the final composition (tablets, capsules, suspensions).
Scope of the Claims
The patent primarily covers:
- A pharmaceutical composition of a specific drug-cyclodextrin inclusion complex, especially where cyclodextrin is anhydrous.
- Methods of preparing such complexes using certain processes.
- Variations with different cyclodextrin derivatives and ratios.
- Applications in oral dosage forms with improved bioavailability.
The claims do not cover all potential drug-cyclodextrin complexes broadly but center on particular drugs (e.g., itraconazole) and specific preparation methods.
Patent Landscape
Prior Art Analysis
- The patent builds on the established use of cyclodextrins in improving drug solubility, evident from prior patents such as U.S. Patent 5,135,680 (Hansen et al.), which discusses cyclodextrin complexes.
- Its novelty stems from specific preparation methods (e.g., spray drying) and particular formulations with anhydrous cyclodextrins.
- The patent's claims are narrowly focused on certain drugs, especially itraconazole, and specific cyclodextrin derivatives.
Related Patents and Applications
- U.S. Patent 5,073,543 covers cyclodextrin complexes but predates 7,431,943 and lacks the specific combination of spray-dried, anhydrous complexes.
- European Patent EP 1,109,844 describes similar complexes, emphasizing stability.
- Numerous applications relate to pharmaceutical formulations using cyclodextrins, but few with the specific process claims as in 7,431,943.
Patent Thickets and Freedom to Operate
- The landscape includes multiple patents covering various cyclodextrin derivatives and complexation methods.
- The scope of 7,431,943 is focused, reducing potential overlap but requiring careful navigation around derivative claims and process-specific limitations.
- Patent life expires soon unless extended, influencing freedom to operate for new formulations.
Strategic Insights
- The patent is valuable for formulations involving itraconazole and similar poorly soluble drugs with cyclodextrins.
- Its focus on anhydrous cyclodextrin complexes and specific preparation methods offers opportunities for alternative processes or derivatives to circumvent claims.
- Commercialization around oral formulations can leverage this patent, provided prior art and process claims are carefully considered.
Key Takeaways
- U.S. Patent 7,431,943 covers drug-cyclodextrin complexes, especially involving itraconazole, with specific preparation processes.
- The scope is narrowly defined around particular drugs, derivatives, and processing methods.
- The landscape involves prior patents on cyclodextrins, with a focus on improving solubility and stability.
- The patent is approaching expiration, influencing strategic planning for R&D or licensing.
- Alternatives or improvements may involve different cyclodextrin derivatives or process modifications.
FAQs
Q1: Does the patent cover all cyclodextrin-drug complexes?
No, it specifically covers complexes involving certain drugs like itraconazole and particular preparation methods.
Q2: Can new methods for forming drug-cyclodextrin complexes bypass this patent?
Potentially, if the methods differ substantially from the processes claimed, especially regarding the use of anhydrous cyclodextrins or specific process steps.
Q3: Is the patent still enforceable?
Only until around 2024, unless extended or subject to legal challenges.
Q4: Are there any drugs other than itraconazole covered?
Yes, claims also encompass other drugs with similar complexation, but details specify particular drugs and ratios.
Q5: How does this patent impact product development?
It constrains formulations involving similar cyclodextrin-drug complexes prepared via described processes, requiring either licensing or alternative approaches.
References
- Hansen, B., et al. (1998). Cyclodextrin complexes and processes for their preparation. U.S. Patent 5,135,680.
- European Patent Office. (2004). Cyclodextrin drug complexes, EP 1,109,844.
- U.S. Patent and Trademark Office. (2008). Patent 7,431,943.
More… ↓
⤷ Start Trial
|
